Literature DB >> 17309373

Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT.

Mike Emmans Dean1, Morag K Coulter, Peter Fisher, Kim A Jobst, Harald Walach.   

Abstract

When homeopathy is tested in clinical trials, understanding and appraisal is likely to be improved if published reports contain details of prescribing strategies and treatments. An international Delphi panel was convened to develop consensus guidelines for reporting homeopathic methods and treatments. The panel agreed on 28 treatment- and provider-specific items that supplement the CONSORT (Consolidated Standards of Reporting Trials) Statement items 2, 3, 4, and 19. The authors recommend these for adoption by authors and journals when reporting trials of homeopathy.

Mesh:

Year:  2007        PMID: 17309373     DOI: 10.1089/acm.2006.6352

Source DB:  PubMed          Journal:  J Altern Complement Med        ISSN: 1075-5535            Impact factor:   2.579


  11 in total

1.  Homeopathy has clinical benefits in rheumatoid arthritis patients that are attributable to the consultation process but not the homeopathic remedy: a randomized controlled clinical trial.

Authors:  Sarah Brien; Laurie Lachance; Phil Prescott; Clare McDermott; George Lewith
Journal:  Rheumatology (Oxford)       Date:  2010-11-13       Impact factor: 7.580

2.  Testing the nanoparticle-allostatic cross-adaptation-sensitization model for homeopathic remedy effects.

Authors:  Iris R Bell; Mary Koithan; Audrey J Brooks
Journal:  Homeopathy       Date:  2013-01       Impact factor: 1.444

Review 3.  Homeopathy Use in the United States and Implications for Public Health: A Review.

Authors:  Michelle L Dossett; Gloria Y Yeh
Journal:  Homeopathy       Date:  2017-12-22       Impact factor: 1.444

4.  Randomized Controlled Trials of Acupuncture (1997-2007): An Assessment of Reporting Quality with a CONSORT- and STRICTA-Based Instrument.

Authors:  Richard Hammerschlag; Ryan Milley; Agatha Colbert; Jeffrey Weih; Beth Yohalem-Ilsley; Scott Mist; Mikel Aickin
Journal:  Evid Based Complement Alternat Med       Date:  2010-10-03       Impact factor: 2.629

5.  Homeopathy for depression--DEP-HOM: study protocol for a randomized, partially double-blind, placebo controlled, four armed study.

Authors:  Ubiratan C Adler; Stephanie Krüger; Michael Teut; Rainer Lüdtke; Iris Bartsch; Lena Schützler; Friedericke Melcher; Stefan N Willich; Klaus Linde; Claudia M Witt
Journal:  Trials       Date:  2011-02-14       Impact factor: 2.279

6.  Reporting experiments in homeopathic basic research-description of the checklist development.

Authors:  B Stock-Schröer; H Albrecht; L Betti; G Dobos; C Endler; K Linde; R Lüdtke; F Musial; R van Wijk; C Witt; S Baumgartner
Journal:  Evid Based Complement Alternat Med       Date:  2011-03-10       Impact factor: 2.629

7.  STRICTA: is it time to do more?

Authors:  Lizhou Liu; Margot Skinner; Suzanne M McDonough; Priya Kannan; George David Baxter
Journal:  BMC Complement Altern Med       Date:  2015-06-20       Impact factor: 3.659

8.  Individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP study): a randomized, double-dummy, double-blind, placebo-controlled trial.

Authors:  Emma Del Carmen Macías-Cortés; Lidia Llanes-González; Leopoldo Aguilar-Faisal; Juan Asbun-Bojalil
Journal:  PLoS One       Date:  2015-03-13       Impact factor: 3.240

9.  Efficacy of individualized homeopathic treatment and fluoxetine for moderate to severe depression in peri- and postmenopausal women (HOMDEP-MENOP): study protocol for a randomized, double-dummy, double-blind, placebo-controlled trial.

Authors:  Emma del Carmen Macías-Cortés; Leopoldo Aguilar-Faisal; Juan Asbun-Bojalil
Journal:  Trials       Date:  2013-04-23       Impact factor: 2.279

10.  Reporting experiments in homeopathic basic research (REHBaR)--a detailed guideline for authors.

Authors:  B Stock-Schröer; H Albrecht; L Betti; P C Endler; K Linde; R Lüdtke; F Musial; R van Wijk; C Witt; S Baumgartner
Journal:  Homeopathy       Date:  2009-10       Impact factor: 1.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.